While EGCG alone (Cheng et al., 2012) failed to abolish BACE activity in vivo, in combination with ferulic acid (FA), a BACE modulator (Mori et al., 2013), epigallocatechin-3-gallate could block BACE activity in APP/PS1 AD mice and reduced amyloidosis and improved cognitive function (Mori et al., 2019). The gene discussed is APP; the disease is Alzheimer disease.